Foghorn Therapeutics Q2 FY26 net loss narrows to $7.2 million; collaboration revenue rises to $16.1 million
Reuters2026/08/06 11:23- Foghorn Therapeutics posted a Q2 net loss of $7.2 million, narrowing from a $17.9 million loss a year earlier.
- Collaboration revenue rose to $16.1 million from $7.6 million, driven by a $14.2 million cumulative catch-up adjustment tied to updated future costs.
- R&D expenses fell to $18.5 million from $21.8 million, while G&A costs eased to $6.4 million from $6.9 million.
- Cash, cash equivalents, and marketable securities totaled $167.6 million as of June 30, with runway into the first half of 2028.
- The Phase 1 dose-escalation trial for FHD-909 (LY4050784) is advancing with NSCLC as the primary target; selective EP300 degraders remain on track for a 2027 IND.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CADU retransmits S1-S2 sustainability report after CNBV comments
PAMT director and 10% owner Matthew T. Moroun disposes of 3,268,000 shares worth $31.22 million
"I am now the market maker, if you want to bet against me, go ahead" Besant warns the market not to short the yen against him
Bessent stated, "When we intervene in the yen, I know exactly what the Japanese, the Bank of Japan, and Japanese policymakers are going to do." With fundamental support from the Bank of Japan's expected 25 basis point rate hike this month, short-sellers will face the dual pressure of policy intervention and an interest rate shift. Analysts believe that Bessent's tough rhetoric serves both as psychological pressure and as an indication that further actions are being prepared.
Crypto prices
More
